Aspira Women's Health Inc. announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare & Medicaid Services (CMS) has approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1. Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024. "Cross walking" refers to a process for setting the Medicare reimbursement rate for a new laboratory test by assigning the new code the same rate as a comparable existing test.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.213 USD | -0.21% | -2.04% | -21.25% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.25% | 39.68M | |
-18.16% | 11.13B | |
+58.43% | 3.6B | |
-31.31% | 2.26B | |
-14.31% | 2.16B | |
-26.61% | 1.54B | |
+34.35% | 1.17B | |
-3.28% | 744M | |
-22.75% | 482M | |
-40.20% | 432M |
- Stock Market
- Equities
- AWH Stock
- News Aspira Women's Health Inc.
- Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services